This opportunity funds research projects aimed at adapting and clinically validating molecular, cellular, and imaging biomarkers for cancer detection, diagnosis, prognosis, monitoring, and prediction of treatment response. It supports acquisition of well-annotated specimens and encourages multidisciplinary teams including assay developers, clinicians, statisticians, and clinical laboratory scientists. Early-stage technology development and clinical trials are excluded.
Eligible applicants include a wide range of U.S. organizations such as public housing authorities, nonprofits, state and local governments, for-profit organizations, tribal governments, and institutions of higher education. Specific eligibility details are provided in the full announcement.
